Sherilyn Alvaran Tuazon MD MS

PubMed

• A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.
  Sherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, Andrew J Cowan, Gabriel O Cole
  Blood. 2025-04-08
• 2 citations
  Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.
  Andrew J Portuguese, Min Fang, Sherilyn A Tuazon, Margot Pont, Xiaoyu Qu
  Blood Advances. 2023-12-12
• 55 citations
  Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
  Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie
  Lancet. 2023-08-19

Abstracts/Posters

• Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...
  Sherilyn A. Tuazon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018